Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

• Status: Completed
• Trial end date: 2019-08-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective randomized double-blind controlled trial assessing the benefits of intramuscular ketorolac before or immediately after office ureteral stent removal.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• patients 18 to 79 who have undergone a cystoscopy with indwelling double-J ureteral stent placement at Clements University Hospital and are presenting to the office for cystoscopy and stent removal.

Exclusion Criteria:

• eGFR <50

• any active or history of peptic ulcer disease or GI bleeding

• Bleeding disorder, suspected of confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis

• Concurrent use of Aspirin 325mg, wafarin, rivaroxaban, apixaban, clopidogrel, or heparin

• Allergic reaction to NSAIDs

• Concurrent use of other NSAIDs within 24 hours

• Pregnancy (ketorolac contraindicated in this population)

• Recent myocardial infarction (MI)